Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial

Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in Chinese adult patients infected with severe a...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2023-12, Vol.102 (51), p.e36714-e36714
Main Authors: Xu, Jianchao, Song, Jinzhong, Xie, Ziyu, Yang, Jie, Wu, Di, Liu, Fengshuang, Zhao, Yinuo, Zang, Hongmin, Zhao, Yubin
Format: Article
Language:English
Subjects:
Adult
Clinical Trial/Experimental Study
COVID-19
COVID-19 Drug Treatment
Hospitals
Humans
Nucleic Acids
Ritonavir - therapeutic use
SARS-CoV-2
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33
cites cdi_FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33
container_end_page e36714
container_issue 51
container_start_page e36714
container_title Medicine (Baltimore)
container_volume 102
creator Xu, Jianchao
Song, Jinzhong
Xie, Ziyu
Yang, Jie
Wu, Di
Liu, Fengshuang
Zhao, Yinuo
Zang, Hongmin
Zhao, Yubin
description Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in Chinese adult patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. This non-randomized clinical controlled trial recruited patients infected with SARS-CoV-2 Omicron variant from the designated hospital for treating COVID-19 between November 5 and November 28, 2022, in Shijiazhuang, China. Participants were administered Paxlovid (300 mg of nirmatrelvir and 100 mg of ritonavir orally) or standard treatment. The primary outcome was the nucleic acid shedding time and post-COVID-19 condition. A total of 320 patients infected with SARS-CoV-2 Omicron variant were included, with mean age of 29.10 ± 7.34 years old. Two hundred patients received Paxlovid. Compared to patients in the standard treatment group, those in Paxlovid group had a significantly shorter nucleic acid shedding time (3.26 ± 1.80 vs 7.75 ± 3.68 days, P 
doi_str_mv 10.1097/MD.0000000000036714
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10735069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2905525611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33</originalsourceid><addsrcrecordid>eNpdkd9uFCEUxonR2G31CUwMl95QYZiBGW_MZtfWTdpsY7W3hAHGxTAwArP-eae-o9TWVuUGAt_3O4fzAfCC4GOCO_76fH2MHxZlnNSPwII0lKGmY_VjsMC4ahDveH0ADlP6gjGhvKqfggPaEloTzBfgejNOUmUYBnghv7uwtxoGD61Hu5Amm6WDYc4qjCZB6TWcQspotb3arBHpoApe22x_G6DUs8twktkan1O5GYzKRsNvNu_g5fLDJVqFK1TB7WhVLJa9jFb6_AYuoQ8exYIPo_1ZHAWbY3Du5uist6p0kYvYPQNPBumSeX63H4FPJ-8-rt6js-3pZrU8Q6rGLCPGeF2Rtq31wHqFe123mjDSykYObdvxCrMOU24066uh4f0wYMxNsXLNpdaUHoG3t9xp7kejVflQlE5M0Y4y_hBBWvHvi7c78TnsRZkpbQq9EF7dEWL4OpuUxWiTMs5Jb8KcRNXhpqkaRkiR0ltpmUpK0Qz3dQgWN0mL87X4P-nievl3i_eeP9HSX6zyplA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2905525611</pqid></control><display><type>article</type><title>Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Xu, Jianchao ; Song, Jinzhong ; Xie, Ziyu ; Yang, Jie ; Wu, Di ; Liu, Fengshuang ; Zhao, Yinuo ; Zang, Hongmin ; Zhao, Yubin</creator><creatorcontrib>Xu, Jianchao ; Song, Jinzhong ; Xie, Ziyu ; Yang, Jie ; Wu, Di ; Liu, Fengshuang ; Zhao, Yinuo ; Zang, Hongmin ; Zhao, Yubin</creatorcontrib><description><![CDATA[Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in Chinese adult patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. This non-randomized clinical controlled trial recruited patients infected with SARS-CoV-2 Omicron variant from the designated hospital for treating COVID-19 between November 5 and November 28, 2022, in Shijiazhuang, China. Participants were administered Paxlovid (300 mg of nirmatrelvir and 100 mg of ritonavir orally) or standard treatment. The primary outcome was the nucleic acid shedding time and post-COVID-19 condition. A total of 320 patients infected with SARS-CoV-2 Omicron variant were included, with mean age of 29.10 ± 7.34 years old. Two hundred patients received Paxlovid. Compared to patients in the standard treatment group, those in Paxlovid group had a significantly shorter nucleic acid shedding time (3.26 ± 1.80 vs 7.75 ± 3.68 days, P < .001), shorter days until negative swab test (1.74 ± 1.15 vs 5.33 ± 2.91, P < .001), shorter days of first symptoms resolution (4.86 ± 1.62 vs 7.45 ± 2.63, P < .001), higher in nucleic acid test negative rate within 3 days [138 (70.77%) vs 14 (11.67%), P < .001], higher negative rate within 5 days [174 (89.23%) vs 26 (21.67%), P < .001], negative rate within 7 days [185 (94.87%) vs 78 (65.00%), P < .001], and were less likely to have post-COVID-19 condition [32 (18.60%) vs 30 (31.57%), P = .016]. There was no significant difference in duration of post-COVID-19 condition (43.00 ± 26.00 vs 49.00 ± 26.34 days, P = .354) between the 2 groups. Compared to standard treatment, Paxlovid significantly reduced nucleic acid shedding time, days until negative swab test, and days of first symptoms resolution, as well as improved nucleic acid test negative rate and post-COVID-19 condition.]]></description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000036714</identifier><identifier>PMID: 38134107</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Adult ; Clinical Trial/Experimental Study ; COVID-19 ; COVID-19 Drug Treatment ; Hospitals ; Humans ; Nucleic Acids ; Ritonavir - therapeutic use ; SARS-CoV-2 ; Young Adult</subject><ispartof>Medicine (Baltimore), 2023-12, Vol.102 (51), p.e36714-e36714</ispartof><rights>Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33</citedby><cites>FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33</cites><orcidid>0000-0003-1981-9297</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735069/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735069/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38134107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Jianchao</creatorcontrib><creatorcontrib>Song, Jinzhong</creatorcontrib><creatorcontrib>Xie, Ziyu</creatorcontrib><creatorcontrib>Yang, Jie</creatorcontrib><creatorcontrib>Wu, Di</creatorcontrib><creatorcontrib>Liu, Fengshuang</creatorcontrib><creatorcontrib>Zhao, Yinuo</creatorcontrib><creatorcontrib>Zang, Hongmin</creatorcontrib><creatorcontrib>Zhao, Yubin</creatorcontrib><title>Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description><![CDATA[Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in Chinese adult patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. This non-randomized clinical controlled trial recruited patients infected with SARS-CoV-2 Omicron variant from the designated hospital for treating COVID-19 between November 5 and November 28, 2022, in Shijiazhuang, China. Participants were administered Paxlovid (300 mg of nirmatrelvir and 100 mg of ritonavir orally) or standard treatment. The primary outcome was the nucleic acid shedding time and post-COVID-19 condition. A total of 320 patients infected with SARS-CoV-2 Omicron variant were included, with mean age of 29.10 ± 7.34 years old. Two hundred patients received Paxlovid. Compared to patients in the standard treatment group, those in Paxlovid group had a significantly shorter nucleic acid shedding time (3.26 ± 1.80 vs 7.75 ± 3.68 days, P < .001), shorter days until negative swab test (1.74 ± 1.15 vs 5.33 ± 2.91, P < .001), shorter days of first symptoms resolution (4.86 ± 1.62 vs 7.45 ± 2.63, P < .001), higher in nucleic acid test negative rate within 3 days [138 (70.77%) vs 14 (11.67%), P < .001], higher negative rate within 5 days [174 (89.23%) vs 26 (21.67%), P < .001], negative rate within 7 days [185 (94.87%) vs 78 (65.00%), P < .001], and were less likely to have post-COVID-19 condition [32 (18.60%) vs 30 (31.57%), P = .016]. There was no significant difference in duration of post-COVID-19 condition (43.00 ± 26.00 vs 49.00 ± 26.34 days, P = .354) between the 2 groups. Compared to standard treatment, Paxlovid significantly reduced nucleic acid shedding time, days until negative swab test, and days of first symptoms resolution, as well as improved nucleic acid test negative rate and post-COVID-19 condition.]]></description><subject>Adult</subject><subject>Clinical Trial/Experimental Study</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Nucleic Acids</subject><subject>Ritonavir - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Young Adult</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdkd9uFCEUxonR2G31CUwMl95QYZiBGW_MZtfWTdpsY7W3hAHGxTAwArP-eae-o9TWVuUGAt_3O4fzAfCC4GOCO_76fH2MHxZlnNSPwII0lKGmY_VjsMC4ahDveH0ADlP6gjGhvKqfggPaEloTzBfgejNOUmUYBnghv7uwtxoGD61Hu5Amm6WDYc4qjCZB6TWcQspotb3arBHpoApe22x_G6DUs8twktkan1O5GYzKRsNvNu_g5fLDJVqFK1TB7WhVLJa9jFb6_AYuoQ8exYIPo_1ZHAWbY3Du5uist6p0kYvYPQNPBumSeX63H4FPJ-8-rt6js-3pZrU8Q6rGLCPGeF2Rtq31wHqFe123mjDSykYObdvxCrMOU24066uh4f0wYMxNsXLNpdaUHoG3t9xp7kejVflQlE5M0Y4y_hBBWvHvi7c78TnsRZkpbQq9EF7dEWL4OpuUxWiTMs5Jb8KcRNXhpqkaRkiR0ltpmUpK0Qz3dQgWN0mL87X4P-nievl3i_eeP9HSX6zyplA</recordid><startdate>20231222</startdate><enddate>20231222</enddate><creator>Xu, Jianchao</creator><creator>Song, Jinzhong</creator><creator>Xie, Ziyu</creator><creator>Yang, Jie</creator><creator>Wu, Di</creator><creator>Liu, Fengshuang</creator><creator>Zhao, Yinuo</creator><creator>Zang, Hongmin</creator><creator>Zhao, Yubin</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1981-9297</orcidid></search><sort><creationdate>20231222</creationdate><title>Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial</title><author>Xu, Jianchao ; Song, Jinzhong ; Xie, Ziyu ; Yang, Jie ; Wu, Di ; Liu, Fengshuang ; Zhao, Yinuo ; Zang, Hongmin ; Zhao, Yubin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Clinical Trial/Experimental Study</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Nucleic Acids</topic><topic>Ritonavir - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Jianchao</creatorcontrib><creatorcontrib>Song, Jinzhong</creatorcontrib><creatorcontrib>Xie, Ziyu</creatorcontrib><creatorcontrib>Yang, Jie</creatorcontrib><creatorcontrib>Wu, Di</creatorcontrib><creatorcontrib>Liu, Fengshuang</creatorcontrib><creatorcontrib>Zhao, Yinuo</creatorcontrib><creatorcontrib>Zang, Hongmin</creatorcontrib><creatorcontrib>Zhao, Yubin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Jianchao</au><au>Song, Jinzhong</au><au>Xie, Ziyu</au><au>Yang, Jie</au><au>Wu, Di</au><au>Liu, Fengshuang</au><au>Zhao, Yinuo</au><au>Zang, Hongmin</au><au>Zhao, Yubin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2023-12-22</date><risdate>2023</risdate><volume>102</volume><issue>51</issue><spage>e36714</spage><epage>e36714</epage><pages>e36714-e36714</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract><![CDATA[Nirmatrelvir plus ritonavir (Paxlovid) have been used in the treatment of adult patients with mild-to-moderate coronavirus disease 2019 (COVID-19). This study aimed to evaluate the impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in Chinese adult patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. This non-randomized clinical controlled trial recruited patients infected with SARS-CoV-2 Omicron variant from the designated hospital for treating COVID-19 between November 5 and November 28, 2022, in Shijiazhuang, China. Participants were administered Paxlovid (300 mg of nirmatrelvir and 100 mg of ritonavir orally) or standard treatment. The primary outcome was the nucleic acid shedding time and post-COVID-19 condition. A total of 320 patients infected with SARS-CoV-2 Omicron variant were included, with mean age of 29.10 ± 7.34 years old. Two hundred patients received Paxlovid. Compared to patients in the standard treatment group, those in Paxlovid group had a significantly shorter nucleic acid shedding time (3.26 ± 1.80 vs 7.75 ± 3.68 days, P < .001), shorter days until negative swab test (1.74 ± 1.15 vs 5.33 ± 2.91, P < .001), shorter days of first symptoms resolution (4.86 ± 1.62 vs 7.45 ± 2.63, P < .001), higher in nucleic acid test negative rate within 3 days [138 (70.77%) vs 14 (11.67%), P < .001], higher negative rate within 5 days [174 (89.23%) vs 26 (21.67%), P < .001], negative rate within 7 days [185 (94.87%) vs 78 (65.00%), P < .001], and were less likely to have post-COVID-19 condition [32 (18.60%) vs 30 (31.57%), P = .016]. There was no significant difference in duration of post-COVID-19 condition (43.00 ± 26.00 vs 49.00 ± 26.34 days, P = .354) between the 2 groups. Compared to standard treatment, Paxlovid significantly reduced nucleic acid shedding time, days until negative swab test, and days of first symptoms resolution, as well as improved nucleic acid test negative rate and post-COVID-19 condition.]]></abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>38134107</pmid><doi>10.1097/MD.0000000000036714</doi><orcidid>https://orcid.org/0000-0003-1981-9297</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2023-12, Vol.102 (51), p.e36714-e36714
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10735069
source HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals; PubMed Central
subjects Adult
Clinical Trial/Experimental Study
COVID-19
COVID-19 Drug Treatment
Hospitals
Humans
Nucleic Acids
Ritonavir - therapeutic use
SARS-CoV-2
Young Adult
title Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A57%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Paxlovid%20on%20in-hospital%20outcomes%20and%20post-COVID-19%20condition%20in%20adult%20patients%20infected%20with%20SARS-CoV-2%20Omicron%20variant:%20A%20non-randomized%20controlled%20clinical%20trial&rft.jtitle=Medicine%20(Baltimore)&rft.au=Xu,%20Jianchao&rft.date=2023-12-22&rft.volume=102&rft.issue=51&rft.spage=e36714&rft.epage=e36714&rft.pages=e36714-e36714&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000036714&rft_dat=%3Cproquest_pubme%3E2905525611%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-667421884df6bc0bd48d1618a5af88972069037ed6b2f57bff007e4067d7add33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2905525611&rft_id=info:pmid/38134107&rfr_iscdi=true